INTRODUCTION
Obesity, defined as an excess of whole-body adipose tissue, has become a global health problem and a leading cause of several chronic illnesses, including type 2 diabetes (WHO, 2010; Yach et al., 2006) . There is increasing evidence that adipose tissue does not simply store energy but is also an essential endocrine organ, producing hormones and secreting growth factors and chemokines (Waki and Tontonoz, 2007) , commonly termed adipokines. These molecules are crucial for both local and systemic communication between adipose and other tissues.
The connection between obesity and metabolic diseases is well established, and increasing efforts are taken to unveil the mechanisms underlying this association. Obesity is accompanied by major changes in the properties of the adipose tissue, including elevated expression of proinflammatory markers, such as CRP, IL-6, TNFa, MCP-1, and MIF (Hotamisligil, 2006; Wellen and Hotamisligil, 2005) . These inflammatory factors are major contributors to the metabolic disease phenotype (Weisberg et al., 2003; Xu et al., 2003) . On the other hand, adiponectin, a hormone produced exclusively by adipose tissue, plays a positive modulatory role in glucose regulation and suppression of the metabolic syndrome and type 2 diabetes (Yamauchi et al., 2001 (Yamauchi et al., , 2002 .
Adipose tissue is characterized by its ability for lifelong growth and almost unlimited expansion. As in other tissues, fat expansion requires concomitant neovascularization to enable delivery of oxygen and nutrients (Cao, 2007; Christiaens and Lijnen, 2010; Hausman and Richardson, 2004; Lijnen, 2008) . To promote neovascularization during its expansion, adipose tissue expresses various angiogenic growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), placental growth factor (PlGF), and leptin (Cao, 2007; Lijnen et al., 2006; Miyazawa-Hoshimoto et al., 2003) .
Similar to tumor neovascularization (Kerbel, 2008) , the critical role of adipose vasculature in tissue growth has generated much interest. Efforts have been made to utilize inhibition of angiogenesis as a potential therapeutic approach for the treatment of obesity and/or diabetes. Indeed, a number of systemically applied angiogenesis inhibitors have shown preliminary efficacy and promise in preclinical models of obesity and metabolic dysfunction (Brå kenhielm et al., 2004; Cao, 2010; Liu et al., 2010; Rupnick et al., 2002) . Several hypotheses have been proposed to explain the inflammatory response of adipose tissue to pathologic expansion, including oxidative stress (Houstis et al., 2006) , endoplasmic reticulum stress (Gregor and Hotamisligil, 2007; Ozcan et al., 2004) , and hypoxia (Hosogai et al., 2007; Trayhurn et al., 2008) . Although these possible mechanisms could be interrelated, hypoxia is likely to play key causal roles in adipocyte dysfunction and the development of insulin resistance (Chi et al., 2006; Goossens et al., 2011; Hosogai et al., 2007; Pasarica et al., 2009 Pasarica et al., , 2010 Wood et al., 2009; Trayhurn et al., 2008; Yin et al., 2009) by inducing inflammation, which in turn leads to massive changes in adipokine profiles and ectopic lipid deposition in insulin sensitive organs. Hypoxia in the adipose tissues of ob/ob and diet-induced obese (DIO) mice has been linked to inadequate angiogenesis (Hosogai et al., 2007; Yin et al., 2009) , which could point to insufficient adipose VEGF signaling as the initiating element of a cascade of events that leads to metabolic diseases.
To shed further light on these events, we developed two kinds of genetically modified mice in which adipose-specific blood vessel density is modulated: adipose-specific deletion of VEGF (VEGF AdD ), and doxycycline-inducible overexpression of VEGF (VEGF AdTg ). Importantly, the specificity of deletion and transgene overexpression is identical. We show that mice selectively deficient for adipose VEGF develop an abnormally sparse adipose vascular network. The decreased vessel density has dramatic negative effects on the metabolic phenotype of these animals. Conversely, adipose-specific expression of VEGF not only protects mice from development of metabolic abnormalities (Hagberg et al., 2010; Liu et al., 2010) but also improves already compromised metabolic functions brought on by a high-fat diet. These findings strongly support our hypothesis that insufficient adipose VEGF signaling initiates a cascade of events that ends with metabolic disease. Furthermore, they show that restoring adequate vessel density in metabolically challenged obese individuals reverts the disease. The latter opens up a new avenue for novel therapeutic approaches.
RESULTS

Adipose-Specific Ablation of VEGF Results in Reduced Vascular Density and Growth of Adipose Tissue
Adipocytes and resident macrophages are the major sources of VEGF in adipose tissues (Cho et al., 2007; Mick et al., 2002; Zhang et al., 1997) . We knocked out VEGF specifically in these two cell types to determine its effect on adipose blood vessel development. We then crossed mice bearing a Cre recombinase-conditional VEGF allele (VEGF loxP ) (Gerber et al., 1999 ) with those harboring an aP2-Cre recombinase transgene (see Figure S1A online). The latter is very well characterized and known to restrict expression to adipocytes and macrophages (He et al., 2003) . Mice with the genotypes marked as ''control'' in Figure S1A were phenotypically indistinguishable from wildtype mice (data not shown).
Adipose tissue-specific VEGF knockout mice (aP2-Cre (+) ; VEGF (loxP,loxP) , hereafter referred to as VEGF AdD ) were born at the expected Mendelian ratio, were viable and fertile, and showed no gross abnormalities (data not shown). Only trace amounts of mRNA and VEGF protein were detected in their white (WAT) and brown (BAT) adipose tissues by quantitative PCR and western blot, respectively ( Figures 1A and 1B) . In contrast, the VEGF mRNA levels in other tissues, such as muscle and liver, and the serum level of VEGF were similar to those of controls ( Figures 1A and 1C) , confirming the adipose-specific loss of VEGF. The gross appearance of WAT from VEGF AdD mice was pale compared to that of the controls ( Figure 1D , panel Gross), suggesting reduced blood perfusion. When blood vessels were visualized by whole-mount immunostaining using a PECAM-1 antibody, it was evident that the vascular densities of both WAT and BAT in VEGF AdD mice were significantly lower than in the control ( Figures 1D [panels PECAM-1] , Figures 1E and 1F) .
To rule out the possibility of an autocrine effect of VEGF modulation on adipocyte function, we studied two gene-targeted mouse lines with lacZ knocked into the loci for either the Flk1 (Ema et al., 2006) or the Flt1 (Fong et al., 1995) VEGF receptors. X-gal-stained WAT and BAT from these mice revealed that the receptors were expressed by endothelial cells ( Figure S1B , yellow arrowheads), but not by white or brown adipocytes (Figure S1B, red arrows) . We therefore conclude that the effect of VEGF on adipose function is manifested in a paracrine manner through blood vessels.
Given the critical importance of adequate angiogenesis for tissue growth, we inferred that reduced adipose vascularization in VEGF AdD mice may hinder fat tissue expansion and, consequently, body weight gain. Consistent with this expectation, the juvenile body weight of these animals was slightly lower than that of controls ( Figure 1G ). Magnetic resonance-assisted measurements of body composition revealed a significant reduction in their fat mass, while their lean mass remained similar to controls ( Figure 1H ). Subsequent weight measurements of fat tissues harvested from these mice showed that the reduction in fat weight was more prominent in perigonadal (PGF) than in subcutaneous fat (SCF) ( Figure 1I ). Since Cre-recombinase activity level is identical in these two tissues (data not shown), these findings indicate a higher sensitivity of perigonadal fat to adipose VEGF deletion than that of subcutaneous fat. The adipocyte size in WAT and weight of the BAT in the VEGF AdD mice was not significantly different from those of controls (data not shown). Furthermore, histological examination of the liver and skeletal muscle did not reveal any difference between experimental groups (data not shown). In summary, the above studies showed that adipose VEGF ablation decreased fat tissue vascularity with a concurrent fat mass reduction in WAT.
Altered Adipokine Expression in the WAT of VEGF AdD Mice Next, we investigated the changes in metabolic parameters and the gene expression level on a panel of thermo-and lipogenic genes in 12-to 16-week-old VEGF AdD animals. The reduced vascularization ( Figure 1D , middle panel, and Figure 1E ) was accompanied by a significantly reduced population of endothelial cells in the WAT, indicated by a decreased level of VEGFR-2 in this tissue (Flk1; Figure 1J ). We found no differences in food consumption ( Figure S1C ), serum triglyceride (TG) (data not shown), or fasting glucose levels, or in intraperitoneal glucose tolerance tests ( Figure S1D ). Furthermore, similar serum insulin levels (data not shown) indicated a normal glucose homeostasis in VEGF AdD animals. While mRNA levels of most adipogenic or adipose secreted factors were unchanged ( Figure S1E ), the expression of adiponectin, an antidiabetic adipokine, was significantly reduced (Figure 1K ), and expression of TNF-a, a proinflammatory cytokine, was significantly elevated (Figures 1L ). Fasting free fatty acid (FFA) in the serum was the same as in the control. Oral lipid challenge, however, dramatically increased FFA in VEGF AdD animals, indicating a defective lipid handling capability ( Figure 1M ).
Interestingly, some of the thermo-and lipogenic gene expression levels were lower in the BAT of the VEGF AdD animals ( Figure S1F ), but this decrease did not affect the energy expenditure and ambulatory activity ( Figures S1G and S1H ) of the animals. (M) Serum-free fatty acid level at fasting and 3 hr after oil gavage (n = 7 for both groups). All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005. Scale bars, 0.5 cm in (D) upper panel and 100 mm in all microscopic images.
VEGF
AdD Mice Develop Metabolic Defects and Insulin Resistance on a High-Fat Diet Although VEGF AdD animals were slightly leaner than the controls, they developed a mild metabolic impairment when kept on standard chow (SC). This finding prompted us to challenge these animals with a high-fat diet (HFD, 60% of calories from fat), expecting an accelerated development of their metabolic disease. We based this expectation on the observation of increased adipose VEGF expression on HFD both in normal (Figure S2A) and in ob/ob mice (Halberg et al., 2009) . From 12 weeks of age, the experimental and control mice were kept on HFD, and their body weights were monitored. During the first 3 weeks, the VEGF AdD animals showed only a slightly lower weight gain than controls; however, over time, a wider difference ( Figure 2A ) and less fat mass development became apparent in these animals ( Figure 2B ), while the size of the adipocytes remained comparable ( Figure S2B ). Freshly harvested WAT from VEGF AdD animals were darker than that of the controls ( Figure 2C , panel Gross), and histological examination revealed high levels of inflammatory cell infiltration into the VEGF-deficient tissues ( Figure 2C , panel
Interestingly, many brown adipocytes in VEGF AdD mice resembled a white adipocyte-like unilocular, rather than a typical multilocular, morphology (Figure 2C, panel BAT [H&E] ). In the livers of VEGF AdD animals, numerous cytoplasmic vacuoles were localized around the portal veins (data not shown) and were present in the hepatocytes close to the hepatic sinusoidal endothelium (Figure 2C, panel Liver [toluidine] and panel Liver [TEM] ). The electron density of these vacuoles was comparable to that of the lipid droplets in adipocytes (data not shown), which was consistent with the increased liver triglyceride level of the VEGF AdD animals ( Figure 2D ). Thus the pathological manifestation of a HFD challenge was presented in both white and brown adipose tissue, as well as in the hepatocytes of the VEGF AdD mice, implying that these animals may have global defects in their metabolic homeostasis. Although there were no differences in fasting blood glucose levels and in expression of Fabp4 and VEGF in liver and muscle ( Figures S2C and S2D ) after 18 weeks on HFD, the VEGF AdD animals showed significantly elevated total cholesterol (Figure 2E ) and decreased fasting level of FFA levels in the serum ( Figure 2F ). More importantly, the VEGF AdD animals developed severe insulin resistance ( Figure 2G ) and glucose intolerance ( Figure 2H ). 3D) , possibly marking the location of apoptotic adipocytes where macrophages are performing their scavenging function (Cinti et al., 2005; Strissel et al., 2007) . Elevated numbers of active caspase-3-positive cells in VEGF AdD adipose tissue further supported this finding (Figures 3F and 3G) . Consistent with these observations, expression of inflammatory genes such as plasminogen activator inhibitor-1 (PAI-1), TNF-a, and macrophage chemotactic factor-1 (MCP-1) were . All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005. Scale bars, 0.5 cm in (C) upper panel and 100 mm in all microscopic images. also increased, while the expressions of adiponectin and PPARg were significantly decreased ( Figure 3H ) in these mice. On the other hand, we did not find significant changes in apoptotic cell numbers and inflammatory cell infiltration in the BAT of VEGF AdD animals (data not shown) kept on HFD. Although we found decreased expression of some lipogenic genes in the BAT ( Figure S3A ), this did not result in any significant differences in energy expenditure or in total activity level (Figures S3B and S3C) . Since the adipose tissue in VEGF AdD mice was poorly vascularized, we investigated whether hypoxia could be part of the mechanism leading to adipocyte apoptosis. We detected significantly reduced vascular perfusion in the WAT of the VEGF AdD animals ( Figures 4A and 4B ). Consistent with this phenotype, the visualization of hypoxic areas by pimonidazole immunostaining of whole-mount adipose tissue revealed a 3-fold increase in hypoxic areas in VEGF AdD mice compared to controls ( Figures  4C and 4D) . We also compared the degree of hypoxia under different dietary conditions ( Figure S4 ). Similar to findings in earlier studies (Hosogai et al., 2007) , HFD resulted in increased adipose hypoxia compared to SC. The effect of HFD on adipose hypoxia was much more pronounced in VEGF AdD mice than in control animals ( Figure S4 ). Our results suggest that hypoxia is associated with adipocyte apoptosis and macrophage infiltration. This inflammation in the adipose tissue leads to abnormal production of adipokines and ectopic lipid depositions, to the known cause of glucose intolerance and insulin resistance (Virtue and Vidal-Puig, 2010; Weisberg et al., 2003; Xu et al., 2003) .
Taken together, these data indicate that adipose VEGF is critical for maintaining the viability and metabolic/endocrine function of adipocytes through its role in regulating adequate vascularization and blood perfusion.
Generation and Characterization of Adipose-Specific Inducible VEGF164-Overexpressing Genetic Model Our loss-of-function studies clearly showed the critical role of adipose VEGF and vessel density and suggested that hypoxia might be the cause for adipose dysfunction. We therefore expected that experimentally increased blood vessel density in . (F and G) (F) Immunofluorescent staining of whole-mount WAT with caspase-3 antibody and (G) its quantification (n = 6 for both groups). (H) Gene expression analysis by qPCR (n = 5-9 per each group). All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005. Scale bars, 100 mm in all microscopic images. adipose tissue would have an opposite effect: reverting HFDinduced metabolic defects to a normal state. To this end, we crossed three well-characterized transgenic mouse lines: mice carrying a Cre recombinase conditional rtTA knockin into the Rosa26 locus (Belteki et al., 2005) , a tet-O-VEGF164 (Akeson et al., 2003) , and an aP2-Cre transgene (He et al., 2003) . Triple transgenic animals ( Figure 5A , designated VEGF AdTg ) were expected to overexpress VEGF164 exclusively in adipocytes and macrophages in a doxycycline (DOX)-inducible manner with the same specificity as the VEGF deletion in our loss-of-function model.
The appearance of the adipose tissue, blood vessel density, and adipocyte size in noninduced VEGF AdTg mice was similar to that of controls, indicating that the transgene is silent in the absence of DOX (data not shown). To avoid possible negative effects (such as increased vascular permeability) of continuous VEGF164 induction (Ozawa et al., 2004) , we applied a metronomically alternating DOX-on and DOX-off treatment regime consisting of a 4 day feeding period with SC followed by a 3 day feeding with doxycycline-containing SC (Standard/DOX diet regime, Figure 5B) . After two cycles of this diet regime, freshly harvested WAT of DOX-treated VEGF AdTg animals appeared more vascularized compared to control mice (single or double transgenic ). All data are presented as mean ± SEM. **p < 0.01, ***p < 0.005. Scale bars, 100 mm in all microscopic images.
littermates; Figure 5C , upper panels). Whole-mount immunostaining with a PECAM-1 antibody revealed increased vascular density (Figures 5C, lower panels; Figure 5D ) with numerous sprouting vascular tip cells, indicating that VEGF164 transgene induction resulted in active angiogenic processes in the adipose tissue of DOX-treated VEGF AdTg animals ( Figure 5C , lower panel, inset). There were no significant differences in body weight gain or food consumption between the two groups ( Figure 5E and Figure S5A ) during the observed period. Furthermore, we did not find any difference in random serum glucose levels ( Figure 5F ), intraperitoneal glucose tolerance, or insulin tolerance ( Figures S5B and S5C) .
We continued to characterize our adipose-specific inducible VEGF transgenic system in animals on HFD challenge. First we tested if we could recapitulate a recently published finding (Elias et al., 2012; Sun et al., 2012) that VEGF activation in adipose tissue at the time of HFD exposure protects animals from metabolic disease development. Similarly to the characterization on SC, here we applied the metronomic alternation of DOX-on and DOX-off treatment regime consisting of a 4 day feeding period with normal HFD followed by 3 day feeding with doxycycline containing high-fat chow (HFD/DOX diet regime) (Figure S6A) . Four days after the start of the HFD feeding, we activated VEGF expression in the VEGF AdTg animals using seven cycles of the HFD/DOX diet regime. The treatment resulted in a significant increase in VEGF164 expression both in WAT and in BAT, but not in the liver ( Figure S6B ). There was no difference in food intake, body weight gain, fat composition, fasting blood glucose levels, serum FFA, TG, total cholesterol, or glucose tolerance (data not shown) between the groups. However, while the control animals developed insulin resistance and hyperinsulinemia, the VEGF164-induced animals were protected from these ( Figures S6C and S6D) . Consistent with our loss-of-function analysis, WATs from control mice showed increased inflammatory cell infiltration ( Figure S6E , panel WAT, arrowheads). We also observed elevated lipid deposition in the BAT and liver ( Figure S6E , panel BAT [H&E] and Liver [H&E] ) and enlarged islet cell mass ( Figure S6E , panel Pan [H&E] ). Therefore, we concluded that when VEGF induction and HFD challenge were applied simultaneously, aP2-specific induction VEGF protects animals from HFD-induced metabolic defect and insulin resistance. We then attempted to identify the mechanism underlying the protective effect of VEGF in these mice and investigated whether it was mediated through the modulation of adipose vessel density and hypoxia. Whole-mount PECAM-1 staining showed an increased vascular network in the adipose tissue of the DOX-induced VEGF AdTg animals ( Figure S6F , panel PECAM-1), resulting in increased tissue perfusion compared to that of the controls ( Figure S6F , panel Microbubble). Consistent with these observations, hypoxia was significantly decreased in the WAT of VEGF AdTg mice ( Figure S6F , panel Pimonidazole), which was accompanied by higher expression of adiponectin and PPARg and lower expression inflammatory cytokine TNF-a ( Figure S6G ). The level of circulating adiponectin was also significantly higher in VEGF AdTg animals ( Figure S6H ). Decreased hypoxia was associated with a lower level of caspase-3 expression ( Figure S6G ), reduced caspase-3-positive cell number (Figures S6I and S6J) , and inflammatory cell infiltration in the adipose tissue of VEGF AdTg mice compared with controls (Figure S6E, panel WAT) . Although adipocyte size was reduced, we did not detect significant differences in blood vessel density or thermo-and lipogenic gene expression pattern in the BAT and energy expenditure of two groups ( Figures S6K-S6M) , suggesting a moderate effect of VEGF164 on morphological and functional changes in BAT.
Transgenic Expression of VEGF164 Reverts High-FatDiet-Induced Glucose Intolerance
We then asked if VEGF activation in the adipose could revert an already established metabolic disease induced by HFD. First we challenged the VEGF AdTg (and controls animals) with HFD in the lack of doxycycline for 8 weeks. Then we applied four cycles of metronomic treatment of HFD/DOX diet regime ( Figure 6A ). The animal's body weight and glucose tolerance were monitored at Start and Term as well as weekly during the study (Figures 6B and 6C) . After 8 weeks of HFD feeding (at Start), glucose clearance was delayed in both groups-reflected by high AUC values-indicating their glucose intolerant status ( Figure 6C , at Start). After four metronomic cycles of the HFD/DOX diet (at Term), we found a surprising reversal effect on glucose intolerance accompanied with dramatic reduction in body weight and (E) Fasting blood glucose level after ten cycles of Standard/DOX diet regime (n = 7 for both groups). All data are presented as mean ± SEM. *p < 0.05. Scale bars, 0.5 cm in (C) upper panel and 100 mm in all microscopic images.
Cell Metabolism
Regulatory Role of Adipose VEGF in Metabolism hepatic lipid deposition (Figures 6B and 6C [Term] , Figure 6D ). Besides the known, general glucose lowering effect of Dox treatment (Basaria et al., 2002; Garbitelli, 1987; Odeh and Oliven, 2000) , our treated VEGF AdTg animals showed improved glucose tolerance compared to the controls ( Figure 6C , Term). This result is the first testament that a diagnosed metabolic disease is reversed by induced expression of adipose VEGF. These data prompted us to challenge the 8 week HFDexposed VEGF AdTg mice with more aggressive DOX treatment and then a longer no-DOX time ( Figure 7A ). At Start we exposed animals to DOX for 2 weeks followed by 2 weeks of no DOX. At the start of the doxycycline treatment, the groups did not differ in their body weight, food consumption, or glucose tolerance ( Figures 7B and 7C , Figures S7A and S7B) . Similarly to the previous experiment, the high AUC indicated that glucose intolerance developed in both groups ( Figure 7C , left panel). After feeding with HFD+DOX for 2 weeks, VEGF AdTg mice showed a significant reduction in total body weight ( Figure 7B ), mostly due to the reduction of fat mass ( Figure S7C ). Most importantly, these mice showed significant improvement in glucose tolerance ( Figure 7C , middle panel, and Figure S7D , middle panel DOX ENDs), while their circulating adiponectin was increased (Figure S7E ). This improvement, however, was found to be VEGF induction dependent; the metabolic compromise rapidly reestablished 2 weeks after the doxycycline treatment was stopped ( Figure 7C , right panel, and Figure S7D , right panel).
We then evaluated whether increased vascular densities, and the resulting decrease in tissue hypoxia and inflammation, could be the possible mechanisms for the metabolic improvement in these animals. Indeed, we could observe reduced adipocyte size ( Figure 7D , upper panels), increased vascular density (Figure 7D , middle panels), and reduced adipose hypoxia ( Figure 7D , bottom panels) in VEGF AdTg mice. Moreover, inflammatory CD11b and F4/80 double positive macrophage infiltration was also reduced in these animals ( Figures 7E and 7F ), which could further contribute to their metabolic improvement. There was no difference between the groups in food intake, rectal body temperature, fecal lipid content, energy expenditure, or serum lipid (FFA and TG) at Start and Term of the HFD/DOX regime (data not shown).
In summary, these data strongly suggested that adiposespecific VEGF164 expression could reverse metabolic anomalies. This reversal is mediated by suppression of hypoxia, inflammation, and apoptosis in the WAT. This leads to the restoration of normal secretion of adipokines and the inhibition of lipid accumulation in insulin-sensitive nonadipose tissues, and therefore improved metabolic homeostasis.
DISCUSSION
The development of obesity-related pathologic conditions, such as fatty liver, cardiovascular diseases, and type 2 diabetes, has many underlying contributory elements, including nutritional status, lifestyle, and complex genetic factors. Mouse models have been used intensively to study the mechanisms behind the pathogenesis of these diseases (Hosogai et al., 2007; Yin et al., 2009) . Hypoxia due to insufficient vascularization of the adipose tissue has been suggested as one important contributing factor (Hosogai et al., 2007) . Recent human studies have confirmed that low vascular density in adipose tissues is directly associated with an abnormal metabolic profile (Pasarica et al., 2009 (Pasarica et al., , 2010 . Obese patients often show decreased circulation and reduced perfusion rates in adipose tissues, which suggests that adipose hypoxia may play a role in the development of metabolic defects (Pasarica et al., 2009 (Pasarica et al., , 2010 . These studies propose that adipose tissue hypoxia might be a link between obesity and its metabolic consequences. However, it is not clear whether hypoxia is a cause or a consequence of obesity-related metabolic disease. VEGF is the key regulator of angiogenesis (Carmeliet, 2003; Folkman, 1995) . In a variety of tissues, changes in VEGF activity positively correlate with microvascular density and hence blood perfusion, which governs the oxygenation of tissues (Baffert et al., 2006; Kamba et al., 2006) . In adipose tissue, VEGF expression is differentially regulated depending on the anatomical locations of the fat depot and dysregulated in obese individuals (Cao, 2007; Goossens et al., 2011; Halberg et al., 2009; Liu et al., 2010; Miyazawa-Hoshimoto et al., 2005; Pasarica et al., 2009) . To alter tissue perfusion via modulation of adipose blood vessel density, we employed genetically engineered mouse models to generate VEGF deficiency (i.e., loss of function, LOF) or doxycycline-inducible overexpression (i.e., gain of function, GOF) restricted to the adipose tissue. In both cases, the well-characterized aP2-Cre transgenic mice (He et al., 2003) provided the desired specificity. The aP2 promoter is active in white and brown adipocytes as well as macrophages (Fu et al., 2000; Furuhashi et al., 2008; Makowski et al., 2001) , rendering it ideally suited to generate adiposespecific VEGF alterations. Although the adipose specificity of the aP2-Cre transgene is well characterized, there are reports indicating that a HFD could induce ectopic aP2 expression in other metabolically important organs (Segal et al., 1992) . Therefore, we evaluated the expression of Fabp4 (aP2) and VEGF levels in the liver and muscles. We did not detect any changes in these tissues ( Figure S2D ), which ruled out the possibility that other organs played direct VEGF level-dependent roles in the development of the VEGF AdD and VEGF AdTg phenotypes. Young animals challenged with a HFD developed severe hypoxia, adipocyte apoptosis, and inflammation, which eventually led to insulin resistance. The associated lipid accumulation in insulin-sensitive organs further suggested that the vascular network in adipose tissue is a critical determinant for adipose lipid storage capacity. When the low vessel density-determined storage capacity of the adipose tissue was surpassed, lipid was deposited into ectopic sites including brown fat, liver, and muscle. The ectopic fat is likely to cause lipotoxicity in the liver and muscles, contributing to the development of insulin resistance (Kim et al., 2007; Savage, 2009; Virtue and Vidal-Puig, 2010) . We showed that the VEGF-induced vessel density increase in the adipose led to the reversal of metabolic morbidities caused by HFD. In these mice, decreased levels of hypoxia and fat inflammation and reduction of adipocyte size were accompanied by the restoration of normal adipose function.
A number of recent publications have investigated the role of VEGF in physiological processes including adipose function (Elias et al., 2012; Lu et al., 2012; Sun et al., 2012) . In addition, another member of VEGF family, VEGF-B, has also been shown to regulate lipid transportation and insulin resistance (Hagberg et al., 2010 (Hagberg et al., , 2012 . These studies, along with our data, highlight the unexpected roles of angiogenic growth factors in wholebody metabolism and unveiled their therapeutic potential for the treatment of metabolic disease and diabetes (Carmeliet et al., 2012) .
In light of both our LOF and GOF findings, it is intriguing and seemingly contradictory that a number of preclinical studies have shown metabolic improvement after treatment with antiangiogenic agents (Gregor and Hotamisligil, 2007; Houstis et al., 2006; Sun et al., 2012) . We believe that a significant part of this discrepancy arises from the systemic nature of inhibition modalities, which could affect metabolically important nonadipose tissues such as liver, skeletal muscle, and heart as well as energy expenditure and the hypothalamic appetite control (Brå kenhielm et al., 2004; Gaemers et al., 2011; Liu et al., 2010; Virtue and Vidal-Puig, 2010) . These systemic effects ) may create unknown influences on whole-body metabolism either directly or indirectly by stimulating other angiogenic growth factors such as VEGF-B, which regulate transendothelial fatty acid transportation in metabolically active organs (Hagberg et al., 2010 (Hagberg et al., , 2012 . These notions further emphasize the necessity of models with adipose-specific VEGF deficiency, like the one reported here.
Another reason could be the fact that systemic antiangiogenic therapies were applied on animals that were already obese (Houstis et al., 2006; Ozcan et al., 2004; Sun et al., 2012) . In our LOF study, however, angiogenesis was reduced in normal adipose tissue. It is possible that in obese individuals, the antiangiogenic treatment of severely hypoxic adipose tissues ablates a large proportion of the failing adipocytes, which gives space for a healthier, less hypoxic regeneration of the adipose tissue.
Regarding our GOF studies, metabolic protection by increased adipose VEGF expression (started prior to HFD feeding) has been already demonstrated (Elias et al., 2012; Sun et al., 2012) . Here we stepped further and asked if adipose VEGF activation (started at the time, when HFD already established metabolic anomaly) could reverse the disease. We found that the increased blood vessel density achieved by VEGF induction in deteriorating fat improves adipose function by increasing blood perfusion, decreasing adipocyte size, reducing hypoxia, and thereby preventing adipocyte apoptosis or necrosis. These findings led to the important notion that obese adipose failure is reversible, mediated by sufficient vessel density determined by VEGF expression. Adipose-VEGF induction reverts the consequence of a cascade of events: adipose hypoxia, adipocyte apoptosis, adipose inflammation, ectopic lipid deposition, and lipotoxicity in metabolically compromised animals, and restores normal glucose homeostasis.
The possibility of adipose-specific modulation of VEGF signaling opens up novel therapeutic avenues to treat type 2 diabetes and the current epidemic of obesity-related metabolic diseases.
EXPERIMENTAL PROCEDURES Animal Maintenance and Studies
All animal care and experimental procedures were approved by the Animal Care Committees of the Toronto Centre for Phenogenomic (TCP). The colony was housed in a specific pathogen-free (SPF) facility in ventilated cages with controlled environment settings (70 F-72 F, 30%-60% humidity), 12 hr light and dark cycles, and ad libitum access to water and food (see the Supplemental Information for more information).
Histologic and Morphometric Analysis
Mouse tissues were prefixed by perfusion with 1% paraformaldehyde in PBS.
WATs were harvested and used as whole mount, while other tissues, including liver and brown adipose tissue after postfixation with 4% paraformaldehyde, were embedded in paraffin for sections and hematoxylin and eosin staining (see the Supplemental Information for more information).
Statistical Analyses
All calculations were performed using PRISM 5.0C software (GraphPad, San Diego, CA, USA) and Microsoft Excel 2011 for Mac. Statistical significance between two groups was determined by the Student's t test using Microsoft Excel and PRISM 5.0C. All data are presented as mean ± SEM. 
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